TY - JOUR
T1 - Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt Syndrome with α-interferon
AU - Hatley, R. M.
AU - Sabio, H.
AU - Howell, C. G.
AU - Flickinger, F.
AU - Parrish, R. A.
PY - 1993/10
Y1 - 1993/10
N2 - Giant vascular neoplasms in neonates generally require aggressive medical or surgical therapy for treatment of complications. Steroids, chemotherapy, embolization, radiation, and surgery have all been used with short-term beneficial and sometimes unknown long-term side effects. A new modality of treatment, α-interferon, has recently been described. The majority of hemangiomas in children involtute by 8 years of age. Occasionally, hemangiomas can endanger vital structures and are associated with a consumption coagulopathy and thrombocytopenia (Kasabach-Merritt Syndrome). These hemangiomas occasionally do not respond to steroids, radiation therapy, cytotoxic drugs, or embolization. The mortality rates approach 50% in nonresponders. Alphainterferon has been used in these children with life-threatening complications of hemangiomas with relief of symptoms. This case illustrates the potential use of α-interferon in the management of giant hemangiomas in children. This emerging form of biological therapy avoids the risks of radiation therapy, embolization, and surgery with only minimal side effects.
AB - Giant vascular neoplasms in neonates generally require aggressive medical or surgical therapy for treatment of complications. Steroids, chemotherapy, embolization, radiation, and surgery have all been used with short-term beneficial and sometimes unknown long-term side effects. A new modality of treatment, α-interferon, has recently been described. The majority of hemangiomas in children involtute by 8 years of age. Occasionally, hemangiomas can endanger vital structures and are associated with a consumption coagulopathy and thrombocytopenia (Kasabach-Merritt Syndrome). These hemangiomas occasionally do not respond to steroids, radiation therapy, cytotoxic drugs, or embolization. The mortality rates approach 50% in nonresponders. Alphainterferon has been used in these children with life-threatening complications of hemangiomas with relief of symptoms. This case illustrates the potential use of α-interferon in the management of giant hemangiomas in children. This emerging form of biological therapy avoids the risks of radiation therapy, embolization, and surgery with only minimal side effects.
KW - Hemangioma
KW - Kasabach-Merritt syndrome
KW - α-interferon
UR - http://www.scopus.com/inward/record.url?scp=0027482740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027482740&partnerID=8YFLogxK
U2 - 10.1016/S0022-3468(05)80327-6
DO - 10.1016/S0022-3468(05)80327-6
M3 - Article
C2 - 8263701
AN - SCOPUS:0027482740
SN - 0022-3468
VL - 28
SP - 1356
EP - 1359
JO - Journal of Pediatric Surgery
JF - Journal of Pediatric Surgery
IS - 10
ER -